GlassScriptPhysician profile
Julia Ann Witte
NPI 1053960807
$2,197.03
in general payments reported to CMS, 2019-2025
32 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $736 · 2023: $284 · 2024: $286 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.87 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $357.35 | 2023-2025 | Veozah |
| Abbvie INC. | $244.04 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.93 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $175.11 | 2021-2025 | Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $128.51 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Edwards Lifesciences Corporation | $124.62 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Otsuka America Pharmaceutical, INC. | $105.46 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.52 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $71.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $66.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.59 | 2022 | |
| Lilly USA, LLC | $55.05 | 2021-2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $49.00 | 2021 | |
| Amgen INC. | $41.15 | 2022-2024 | Evenity, Prolia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $40.11 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $38.69 | 2025 | |
| Hologic Sales and Service, LLC | $36.02 | 2021-2023 | Aptima |
| Novartis Pharmaceuticals Corporation | $31.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.09 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $27.72 | 2021-2024 | Airsupra |
| Xeris Pharmaceuticals, INC. | $22.76 | 2024 | Gvoke Hypopen |
| Aspira Women'S Health INC | $22.00 | 2022 | |
| Exact Sciences Corporation | $20.90 | 2023 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $19.81 | 2025 | Zenpep |
| Ironshore Pharmaceuticals INC. | $17.44 | 2024 | |
| Ascend Therapeutics US, LLC | $17.34 | 2023 | |
| Merck Sharp & Dohme LLC | $14.34 | 2025 | Enflonsia, Vaxneuvance |
| Glaxosmithkline, LLC. | $14.19 | 2024 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $14.12 | 2022 | |
| Axsome Therapeutics, INC. | $13.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Witte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.